In case you missed it yesterday, there was a massive volume surge on ONPH after a major news release dropped Monday. The volume surge


Update On Profile ONPH

April 23rd

Good Morning,

In case you missed it yesterday, there was a massive volume surge on ONPH after a major news release dropped Monday.

At one point ONPH was up yesterday an approximate 122.5% from its Monday Tuesday close. Eventually, ONPH even ended up closing up approximately 105%.

The volume surge (over 6Mn shares) was the highest amount of shares traded in a single day in 2020 and shot ONPH up to levels it hasn't seen in over 2+ months.

Here's the article:

Oncology Pharma Licensor and Co-Development Partner, Kalos Therapeutics, Announces Progress in CV-19 Preventative & Therapeutic Approaches

Oncology Pharma Inc. (OTCPK:ONPH) is pleased to announce further information from it's Licensor, Kalos Therapeutics "Kalos"

PHOENIX, AZ / ACCESSWIRE / April 21, 2020 / Kalos Therapeutics announced its latest progress in its efforts to discover and develop a novel multi-drug cocktail of investigational peptide KTH-222 and immune-stimulating agents that can be administered as prophylaxis before exposure to the [...] virus or as a treatment for immune-compromised cancer patients already infected. The key here will be an opportunity for treating asymptomatic patients. Kalos has identified numerous immune-stimulating agents and will target two based on safety and efficacy, as well as other desirable attributes, to begin development.

George Colberg, CEO of Kalos Therapeutics, said, "Through our network of patients and key opinion leaders we are learning that many patients, that may have a weak immune-system, are reluctant to venture out for the continuation of therapies. Using a multi-drug approach to protect the most vulnerable cancer patients with cardiovascular issues and/or weakened immune-system is an urgent unmet need that is a priority for Kalos Therapeutics." He added, "KTH-222 as a monotherapy and/or in combination with FDA- approved anti-viral therapies or as compassionate drugs will potentially benefit cancer patients at risk including those not yet demonstrating symptoms."

In order to meet the pressing public health need, Kalos is in discussion with BARDA for funding opportunities through BAA and Corona Watch Meeting, collaborative opportunities, to hone strategies, and align with Government priorities to address this unmet need.

Oncology Pharma and Kalos Therapeutics were recently mentioned in the BioWorld website:

Read The Full Article Here.


Your low float (under 20Mn shares) idea is: Oncology Pharma Inc. (ONPH).

Oncology Pharma, Inc. is a pioneering oncology company dedicated to licensing, developing, manufacturing and commercializing therapeutics. The company has assembled a team of executives and advisers with proven multi-disciplinary expertise in the field of oncology, therapeutics and leadership to identify, negotiate and amalgamate “best in class” research, technologies, therapeutics and delivery mechanisms that are synergistic and collaborative. The goal is to create value, reduce costs and increase the speed of regulatory approval and commercialization of effective and safer cancer drugs.

ONPH Website



Talk again shortly.


Kai Parker


(Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided.)

Disclosure: I am not a lice.nsed finan.cial adviser. All potential percentage gains are based on from the low to the high of day. StockWireNews full disclosure is to be read and fully understood before using StockWireNews website, or joining StockWireNews' email or text list. By viewing StockWireNews website and/or reading Stock Wire News email or text newsletter you are agreeing to StockWireNews full disclosure which can be read at Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Stock Wire News (stock wire news . com) is owned by Stock News Wire LLC, a limited liability company. A member of Stock News Wire, LLC owns an interest in the limited liability company that owns and operates small cap firm . com ("SCF") and an interest in the limited liability company that owns and operates fierce analyst . com ("FI"). From time to time, non-affiliated third parties hire Stock Wire News, SCF and/or FI jointly to publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between StockWireNews LLC and World Wide Media Group LLC (a non affiliated 3rd party), StockWireNews has been hired for a period beginning on 4/21/20 and ending on 4/22/20 to publicly disseminate information about (ONPH) via Website, Email and SMS. We have been paid thirty thousand USD via bank wire transfer. We own zero shares of (ONPH).